PPAR agonist 7 是一种具有口服活性的泛 PPAR 激动剂,可有效激活 PPARα (EC50 = 1.51 μM)、PPARδ (EC50 = 1.11 μM) 和 PPARγ (EC50 = 3.14 μM) 全部三种亚型,显著增强脂肪细胞对葡萄糖的摄取且脂肪生成活性极低,能够抑制白色脂肪组织中 PPARγ Ser273 的磷酸化并上调胰岛素增敏基因,在高脂饮食 (HFD)/Streptozotocin (MS-Q80520) (STZ) 诱导的 2 型糖尿病 (T2DM) 模型中不会引起体重增加或体液潴留,可选择性调节 PPAR 信号通路而不激活脂肪生成基因程序,因此可用于糖尿病的研究。
产品编号: MS-U81716 CAS No.: 3122526-69-3 分子式: C29H35NO5 分子量: 477.59
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PPAR agonist 7 是一种具有口服活性的泛 PPAR 激动剂,可有效激活 PPARα (EC50 = 1.51 μM)、PPARδ (EC50 = 1.11 μM) 和 PPARγ (EC50 = 3.14 μM) 全部三种亚型,显著增强脂肪细胞对葡萄糖的摄取且脂肪生成活性极低,能够抑制白色脂肪组织中 PPARγ Ser273 的磷酸化并上调胰岛素增敏基因,在高脂饮食 (HFD)/Streptozotocin (MS-Q80520) (STZ) 诱导的 2 型糖尿病 (T2DM) 模型中不会引起体重增加或体液潴留,可选择性调节 PPAR 信号通路而不激活脂肪生成基因程序,因此可用于糖尿病的研究。

生物实验数据

生物活性 PPAR agonist 7 is an orally active pan-PPAR agonist that effectively activates all three subtypes, PPARα (EC50 = 1.51 μM), PPARδ (EC50 = 1.11 μM), and PPARγ (EC50 = 3.14 μM), significantly enhances glucose uptake in adipocytes with minimal adipogenic activity, inhibits PPARγ Ser273 phosphorylation in white adipose tissue and upregulates insulin-sensitizing genes, does not cause weight gain or fluid retention in a high-fat diet (HFD)/Streptozotocin (MS-Q80520) (STZ)-induced type 2 diabetes mellitus (T2DM) model, and selectively modulates the PPAR signaling pathway without activating the adipogenic gene program, making it useful for the study of diabetes.
体外研究
(In Vitro)

PPAR agonist 7 (Compound 1d) (1-10 μM,24 小时) 对 3T3-L1 脂肪细胞的活力无显著影响,但在测试浓度下,其能以剂量依赖的方式增加成熟脂肪细胞的葡萄糖摄取。
PPAR agonist 7 (10 μM,75 分钟) 可显著抑制 3T3-L1 细胞中 TNFα 诱导的 PPARγ 在Ser273 位点的磷酸化。
PPAR agonist 7 (1-10 μM,24 小时) 可显著恢复暴露于 30 mM 葡萄糖和 0.5 μM 胰岛素的 HepG2细胞的葡萄糖摄取。
PPAR agonist 7 (10 μM,8 天) 可显著减少 3T3-L1 细胞中的脂滴数量,且脂肪生成关键基因 (Ppary、Ap2、Cebpa、Fasn、Cd36、Lpl) 的 mRNA 水平未见显著上调。

Cell Cytotoxicity Assay

Cell Line: 3T3-L1 adipocytes cells
Concentration: 1 μM, 5 μM, 10 μM
Incubation Time: 24 h
Result: Showed no significant effect on the viability of 3T3-L1 adipocytes.

Western Blot Analysis

Cell Line: TNF-α-induced 3T3-L1 cells
Concentration: 10 μM
Incubation Time: Pretreated for 45 min, then stimulation with 50 ng/mL TNF-α for an additional 30 min
Result: Significantly inhibited TNFα-induced phosphorylation of PPARγ at Ser273 in 3T3-L1 cells.

Real Time qPCR

Cell Line: 3T3-L1 adipocytes cells
Concentration: 10 μM
Incubation Time: 8 days
Result: Showed no significant effects on any of these adipogenesis-related genes (Ppary, Ap2, Cebpa, Fasn, Cd36, Lpl).
体内研究
(In Vivo)

PPAR agonist 7 (Compound 1d) (5-20 mg/kg,口服,每日一次,持续 30 天) 显著改善了小鼠 T2DM 模型中的胰岛素敏感性、血糖控制和脂质代谢,且不引起体重增加或体液潴留等副作用。

Animal Model: The male C57BL/6J mice (18-22 g, 4-6 weeks) were fed a high-fat diet 12 weeks and then mice were received daily intraperitoneal injections of streptozotocin (STZ; 50 mg/kg) for five consecutive days, following this, the mice were fed for an additional three weeks to establish the STZ/HFD-induced T2DM model.
Dosage: 5 mg/kg, 10 mg/kg, 20 mg/kg
Administration: P.o., once daily for 30 days
Result: Significantly improved fasting blood glucose levels and reduced fasting insulin concentrations.
Demonstrated dose-dependent improvements in insulin resistance in this diabetic model.
Significantly elevated fasting plasma adiponectin levels in T2DM mice.
Did not cause significant body weight gain and no effect on hematocrit.
Significantly enhanced glucose clearance and insulin sensitivity.
Significantly reduced plasma TG, TC, LDL-C, and FFA; significantly increased plasma adiponectin levels.
Significantly alleviated hepatocellular steatosis and ballooning degeneration; reduced plasma AST and ALT levels.
Inhibited PPARγ Ser273 phosphorylation in WAT; upregulated insulin-sensitive genes (Adiponectin, Cyp2f2).
Selectively regulated insulin resistance-related genes (Glut4, Irs1), but did not activate adipogenesis genes (Ppary, Fasn).

化学信息

分子量 477.59
分子式 C29H35NO5
CAS No. 3122526-69-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础